News

Recent preclinical and clinical results raises hope for an effective HIV vaccine.
U.S. researchers presents data demonstrating the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-...

San Francisco, CA - November 5, 2011 -...

The exploratory pre-specified analysis from the ongoing STARTMRK Phase III study were presented at EACS in Belgrad and IDSA in Boston. STARTMRK is a study of the integrase inhibitor ISENTRESS®(raltegravir) in combination therapy compared to efavirenz in combination...

First large-scale Phase III clinical trial of once-daily dosing for Celsentri/Selzentry in combination with a protease inhibitor in treatment naive HIV patients
 

Newly published article shows that highly active antiretroviral therapy initiated at CD4 cell counts between 350 cells/mcL and 499 cells/mcL was associated with slower disease progression when compared with a deferral strategy, according to new findings published in...

While printing and distributing is going on for Issue 2011-2, you may read the brand new issue as .pdf here.  

                  - New treatment options increase chance of a cure -

Lifetime blood donation ban lifted in UK for men who have had sex with menBritain Department of Health declare in press release updated recommendations for accepted blood donors.The changes will be implemented on Monday 7 November 2011....

WHITEHOUSE STATION, N.J., July 18, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved VICTRELIS™ (boceprevir) for the treatment of chronic hepatitis C (CHC) genotype 1 infection...

Phase 3 telaprevir studies published in New England Journal of Medicine

Pages